ECSP056216A - MODIFIED BUPROPION CHLORHYDRATE RELEASE TABLET - Google Patents

MODIFIED BUPROPION CHLORHYDRATE RELEASE TABLET

Info

Publication number
ECSP056216A
ECSP056216A ECSP056216A ECSP056216A EC SP056216 A ECSP056216 A EC SP056216A EC SP056216 A ECSP056216 A EC SP056216A EC SP056216 A ECSP056216 A EC SP056216A
Authority
EC
Ecuador
Prior art keywords
release tablet
chlorhydrate
modified
release
bupropion
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Werner Oberegger
Okpo Eradiri
Fang Zhou
Paul Maes
Original Assignee
Biovail Lab Int Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40203031&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP056216(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biovail Lab Int Srl filed Critical Biovail Lab Int Srl
Priority to ECSP056216 priority Critical patent/ECSP056216A/en
Publication of ECSP056216A publication Critical patent/ECSP056216A/en

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una tableta de liberación modificada de clorhidrato de bupropion, que comprende (i) un núcleo que comprende una cantidad efectiva de clorhidrato de bupropion, un aglutinante, un lubricante y (ii) un recubrimiento para controlar la liberación que rodea el núcleo y (iii) una barrera contra la humedad que rodea el recubrimiento para controlar la liberación, en done la tableta de liberación modificada es bioequivalente a las tabletas de Wellbutrin® o de Zyban®/Wellbutrin®SR.A modified release tablet of bupropion hydrochloride, comprising (i) a core comprising an effective amount of bupropion hydrochloride, a binder, a lubricant and (ii) a coating to control the release surrounding the core and (iii) a moisture barrier surrounding the coating to control release, where the modified-release tablet is bioequivalent to Wellbutrin® or Zyban® / Wellbutrin®SR tablets.

ECSP056216 2005-12-12 2005-12-12 MODIFIED BUPROPION CHLORHYDRATE RELEASE TABLET ECSP056216A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ECSP056216 ECSP056216A (en) 2005-12-12 2005-12-12 MODIFIED BUPROPION CHLORHYDRATE RELEASE TABLET

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ECSP056216 ECSP056216A (en) 2005-12-12 2005-12-12 MODIFIED BUPROPION CHLORHYDRATE RELEASE TABLET

Publications (1)

Publication Number Publication Date
ECSP056216A true ECSP056216A (en) 2006-10-10

Family

ID=40203031

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP056216 ECSP056216A (en) 2005-12-12 2005-12-12 MODIFIED BUPROPION CHLORHYDRATE RELEASE TABLET

Country Status (1)

Country Link
EC (1) ECSP056216A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11660274B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660273B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11786488B2 (en) 2018-09-20 2023-10-17 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11660274B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660273B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11786488B2 (en) 2018-09-20 2023-10-17 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US12102606B2 (en) 2018-09-20 2024-10-01 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion

Similar Documents

Publication Publication Date Title
MEP3608A (en) Modified-release tablet of bupropion hydrochloride
ECSP077999A (en) FORMULATIONS OF A MODIFIED LIBERATION BUPROPION SALT
CL2018003398A1 (en) Pharmaceutical sustained release composition comprising micro-particles. (application division 2013-03538).
CL2007003797A1 (en) COMPOUNDS DERIVED FROM PIRROLO PIRIDINA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE FOR THE TREATMENT OF THE DISEASE OF ALZHEIMER, PARKINSON, CANCER, AMONG OTHER ILLNESSES.
MX290450B (en) USE OF A COPOLIMERO OF (MET) ANIONIC ACRYLATE, PARTLY NEUTRALIZED, AS A COVER FOR THE PRODUCTION OF A PHARMACEUTICAL FORM THAT RELEASES ACTIVE SUBSTANCE WITH REDUCED PH VALUES.
CL2008000691A1 (en) COMPOUNDS DERIVED FROM DIHIDRO AND TETRAHIDRO OXAZOLOPIRIMIDINONAS REPLACED; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE FOR THE TREATMENT OF CHICHOPHRENIA, EPILEPSY, BETWEEN OTHER DISEASES.
CL2008000369A1 (en) COMPOUNDS DERIVED FROM PYRIDOPIRIMIDINONES; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT PAIN, DEPRESSION, CARDIOVASCULAR DISEASES, RESPIRATORY DISEASES AND PSYCHIATRIC DISEASES.
FR2883179B1 (en) COATED TABLET
CL2010000188A1 (en) A method for treating an infection in a subject comprising the administration of 9 - [(2,2-dimethyl-propylamino) -methyl] -minocycline or a salt thereof; pharmaceutical composition comprising said compound; and its use.
ECSP17000643A (en) Pharmaceutical combination comprising 3- (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and Paracetamol.
CL2013002251A1 (en) Cosmetic composition comprising a silicon compound and a personal care ingredient; aqueous and non-aqueous emulsion. (divisional application 893-2007)
NO20084368L (en) Stable emulsion formulations
CL2012000024A1 (en) Pharmaceutical composition comprising 100 to 2000 mg of metformin and 10 to 300 mg of a glucopyranosyl substituted phenyl derivative sglt-2 inhibitor compound, microcrystalline cellulose, a binder and croscarmellose.
BRPI0815766A2 (en) PESTICIDE COMPOSITION, AND METHOD FOR POTENTIALIZING THE EFFICACY OF AN ACTIVE PESTICIDE INGREDIENT.
CL2007002026A1 (en) COMPOSITION THAT INCLUDES AT LEAST AN IRONING COMBINING COMPOUND AND AT LEAST AN ANTIFUNGIC AGENT; AND METHOD FOR THE TREATMENT OR PREVENTION OF A FUNGICAL CONDITION.
CL2007003800A1 (en) METHOD FOR THE TREATMENT OF OCULAR HYPERTENSION THAT INCLUDES A SMALL MOLECULA AGENT THAT INTERACTS WITH A CODIFYING GENE FOR SERICA AMYLOID PROTEIN A (SAA).
CL2008002629A1 (en) Compounds derived from heterocycles; its preparation process; fungicidal composition comprising said compounds; and method to combat or control phytopathogenic fungi.
CL2007003643A1 (en) PHARMACEUTICAL COMPOSITION OF AZIMILIDINE THAT INCLUDES 0.5% TO APPROXIMATELY 2.5% (W / W) OF WATER; AND USE FOR THE TREATMENT OF CARDIAC ARRITMIAS.
CL2011001122A1 (en) Compounds derived from alkylheterocycles carbamates; preparation procedure; pharmaceutical composition; and its use to prevent or treat acute or chronic pain, neurological and psychiatric pathologies, cardiovascular diseases, among others.
BRPI0720314A2 (en) COMPOSITION, AND, USES OF A Triazole COMPOSITION AND COMPOSITION.
AR065342A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING QUETIAPINE FUMARATE
ECSP056216A (en) MODIFIED BUPROPION CHLORHYDRATE RELEASE TABLET
EP1900368A4 (en) TABLET CONTAINING AN ACTIVE SOLUBLE INGREDIENT
EA200600066A1 (en) Tamsulozine-containing core coated with polyvinylpyrrolidone or polyvinyl acetate
GT200400183A (en) DOSAGE FORMS OF AZITHROMYCIN WITH REDUCED SIDE EFFECTS